PHILADELPHIA, Sept. 30, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, today provided an update on the status of its late-stage development product EUR-1008 (ZENTASE(r)), an innovative pancreatic enzyme replacement product (PEP).
